Sarepta Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
SRPT$17.24-3.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| As of December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $428,430 | $966,777 |
| Short-term investments | 1,247,820 | 1,022,597 |
| Accounts receivable, net | 400,327 | 214,628 |
| Inventory | 322,859 | 203,968 |
| Other current assets | 179,895 | 149,891 |
| Total current assets | 2,579,331 | 2,557,861 |
| Property and equipment, net | 227,154 | 180,037 |
| Right of use assets | 129,952 | 64,954 |
| Non-current inventory | 191,368 | 162,545 |
| Other non-current assets | 136,771 | 162,969 |
| Total assets | $3,264,576 | $3,128,366 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $164,918 | $95,875 |
| Accrued expenses | 314,997 | 418,996 |
| Deferred revenue, current portion | 50,416 | 89,244 |
| Current portion of long-term debt | 105,483 | — |
| Current portion of lease liabilities | 17,845 | 15,489 |
| Total current liabilities | 653,659 | 619,604 |
| Long-term debt | 1,132,515 | 1,544,292 |
| Lease liabilities, net of current portion | 140,965 | 57,578 |
| Deferred revenue, net of current portion | 437,000 | 485,000 |
| Contingent consideration | 38,100 | 36,900 |
| Other non-current liabilities | 3,000 | 42 |
| Total liabilities | 2,405,239 | 2,743,416 |
| Commitments and contingencies (Note 21) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and outstanding | — | — |
| Common stock, $0.0001 par value, 198,000,000 shares authorized; 93,731,831 and 87,950,117 issued and outstanding at December 31, 2023 and 2022, respectively | 9 | 9 |
| Additional paid-in capital | 5,304,623 | 4,296,841 |
| Accumulated other comprehensive income (loss), net of tax | 918 | (1,664) |
| Accumulated deficit | (4,446,213) | (3,910,236) |
| Total stockholders’ equity | 859,337 | 384,950 |
| Total liabilities and stockholders’ equity | $3,264,576 | $3,128,366 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.